NASDAQ · SURF
Surface Oncology, Inc.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
Loading market information…
AMEX · HTBX · USD
Stock price, earnings
Quote as of May 3, 2022, 04:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Heat Biologics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:08 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.42-82.61% vs estimate |
| $849.73K |
| Q2 2020 | Aug 7, 2020 | -$0.35+46.97% vs estimate | $593.17K-44.44% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$0.76$0.00 (0.0%)
The Valens Company Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
$22.47-$0.59 (-2.56%)
Sigilon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.75% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$1.13-$0.08 (-6.25%)
MindWalk Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
